Guidelines and Good Clinical Practice Recommendations for Contrast-Enhanced Ultrasound (CEUS) in the Liver-Update 2020 WFUMB in Cooperation with EFSUMB, AFSUMB, AIUM, and FLAUS.

Dietrich, Christoph F; Nolsøe, Christian Pállson; Barr, Richard G; Berzigotti, Annalisa; Burns, Peter N; Cantisani, Vito; Chammas, Maria Cristina; Chaubal, Nitin; Choi, Byung Ihn; Clevert, Dirk-André; Cui, Xinwu; Dong, Yi; D'Onofrio, Mirko; Fowlkes, J Brian; Gilja, Odd Helge; Huang, Pintong; Ignee, Andre; Jenssen, Christian; Kono, Yuko; Kudo, Masatoshi; ... (2020). Guidelines and Good Clinical Practice Recommendations for Contrast-Enhanced Ultrasound (CEUS) in the Liver-Update 2020 WFUMB in Cooperation with EFSUMB, AFSUMB, AIUM, and FLAUS. Ultrasound in medicine & biology, 46(10), pp. 2579-2604. Elsevier 10.1016/j.ultrasmedbio.2020.04.030

Text 1-s2.0-S0301562920302003-main.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (1MB)

The present, updated document describes the fourth iteration of recommendations for the hepatic use of contrast-enhanced ultrasound, first initiated in 2004 by the European Federation of Societies for Ultrasound in Medicine and Biology. The previous updated editions of the guidelines reflected changes in the available contrast agents and updated the guidelines not only for hepatic but also for non-hepatic applications. The 2012 guideline requires updating as, previously, the differences in the contrast agents were not precisely described and the differences in contrast phases as well as handling were not clearly indicated. In addition, more evidence has been published for all contrast agents. The update also reflects the most recent developments in contrast agents, including U.S. Food and Drug Administration approval and the extensive Asian experience, to produce a truly international perspective. These guidelines and recommendations provide general advice on the use of ultrasound contrast agents (UCAs) and are intended to create standard protocols for the use and administration of UCAs in liver applications on an international basis to improve the management of patients.

Interest & Impact

Downloads

4 since deposited on 19 Nov 2020
0 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item